Non-Hodgkin Lymphoma

Caregivers of patients with cancer may face financial toxicity and stress — with little time to take care of themselves.

The prescription of systemic cancer therapies varies based on a patient’s age, comorbidities, cancer stage and other variables, according to recent research.

The FDA approval of Brukinsa represents another treatment option with fewer side effects in patients with Waldenstrom's macroglobulinema, however it will not serve as a replacement for other therapies.

The FDA approval of Brukinsa, according to an expert from the Dana-Farber Cancer Institute, provides an important new option for targeted therapy in Waldenstrom’s macroglobulinemia.

Bayer, the manufacturer of Roundup, created a five-point plan to decrease the risk of facing future litigation about its product causing cancer.

About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

From Ashley Monroe’s blood cancer diagnosis to a CrossFit athlete’s inspiring cancer journey, here’s what’s happening in the cancer landscape this week.

Treatment with a novel combination therapy was associated with increased efficacy among patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma and was also well tolerated.

The Food and Drug Administration approved the supplemental new drug application for Xalkori (crizotinib) to treat children and young adults between the ages of 1 and 21 with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma.

The FDA has not yet reached a decision on an application for the approval of a CAR-T cell therapy product for the treatment of relapsed/refractory large b-cell lymphoma and, according to Bristol Myers Squibb, a new action date for the decision has not been set.

From a new study showing data that patients with cancer, especially Black patients with cancer, are at a higher risk for COVID-19 than non-cancer patients to NFL punter Rigoberto Sanchez making a speedy recovery after surgery for cancer, here’s what’s happening in the cancer space this week.

For multiple patients with blood cancers who would normally use Rituxan, the Food and Drug Administration has approved the biosimilar Riabni based off highly similar clinical evidence between the two drugs, potentially lowering costs for patients.

The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.

Safety and efficacy observed in this real-world study for patients with non-Hodgkin lymphoma similarly reflect findings from previous pivotal trials.

A novel type of immunotherapy known as chimeric antigen receptor, or CAR, T cell therapy is a hot topic in the news and in the lab. But what does this treatment consist of, and how was it developed?

We have all been told we should stay off our phone before bed, but this study proves that the outdoor light at night is truly harmful long term and could increase the risk of non-Hodgkin lymphoma.

This combined treatment, which includes bendamustine, ofatumumab, carboplatin and etoposide, may serve as an effective bridge to stem cell transplantation.

Finding cancer may be easier now, as blood tests are being developed to diagnose patients with asymptomatic cancer.

CAR-T cell therapy is a relatively new treatment option for patients with blood cancers, but it’s one showing promise across the landscape. Here’s what you need to know.

Outcomes for patients with Hodgkin lymphoma continue to improve, thanks to new drugs, according to Dr. Pamela Allen.

Three targeted drugs have recently been approved to treat diffuse large B-cell lymphoma, broadening the treatment options for patients with this aggressive blood cancer, according to Dr. Germame Ajebo.

Giving fewer courses of chemotherapy and no radiation could become a new standard for patients with stage 1 or 2 diffuse large B cell lymphoma based on the results of a recent study.

CAR-T cell therapy is drastically improving outcomes for patients with diffuse large B-cell lymphoma. However, the treatment can come with some severe side effects that patients need to know about.

Combining the immunotherapy Keytruda with a CAR-T cell therapy that targets the proteins CD19 and CD22 generates complete responses with minimal side effects, results from an early study demonstrate.

A recent approval of the combination of Monjuvi and Revlimid fills an unmet need for certain patients with DLBCL, according to Dr. Gilles Salles.

Heightening the dose of the targeted drug Rituxan (rituximab) during the first four cycles of the R-CHOP regimen does not improve outcomes in treating patients with diffuse large B-cell lymphoma, the phase 3 HOVON-84 trial found.

The agent, in combination with the current standard of care, is being evaluated as a frontline treatment for patients with high-risk Denovo Genomic Marker 1 (DGM1)–positive DLBCL.

The Food and Drug Administration approved Monjuvi in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Here are the top 5 CURE stories for July 2019.